Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

(2019) Jamie N. Justice et al.   EBioMedicine

Sunitinib does not acutely alter left ventricular systolic function, but induces diastolic dysfunction

(2018) Takeshi Wada et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dasatinib increases endothelial permeability leading to pleural effusion

(2018) Carole Phan et al.   EUROPEAN RESPIRATORY JOURNAL

Dependence receptors - the dark side awakens

(2018) Ana-Maria Negulescu et al.   FEBS Journal

Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future

(2018) Baichun Yang et al.   JOURNAL OF APPLIED TOXICOLOGY

Application of human induced pluripotent stem cell-derived cardiomyocytes sheets with microelectrode array system to estimate antiarrhythmic properties of multi-ion channel blockers

(2018) Hiroko Izumi-Nakaseko et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines

(2017) Cécile Mingard et al.   JOURNAL OF APPLIED TOXICOLOGY

Development of correction formula for field potential duration of human induced pluripotent stem cell-derived cardiomyocytes sheets

(2017) Hiroko Izumi-Nakaseko et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Characterization of human iPS cell-derived cardiomyocyte sheets as a model to detect drug-induced conduction disturbance

(2017) Hiroko Izumi-Nakaseko et al.   JOURNAL OF TOXICOLOGICAL SCIENCES

Microfluidic whole blood testing of platelet response to pharmacological agents

(2017) Ruizhi Li et al.   PLATELETS

High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells

(2017) Arun Sharma et al.   Science Translational Medicine

A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes

(2017) Hiroyuki Ando et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

(2016) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential

(2016) Wataru Yamamoto et al.   PLoS One

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

(2015) Yi Zhu et al.   AGING CELL

Utility of Peak Creatine Kinase-MB Measurements in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Outcome After First Anterior Wall Acute Myocardial Infarction (from the INFUSE-AMI Trial)

(2015) Tomotaka Dohi et al.   AMERICAN JOURNAL OF CARDIOLOGY

Cardiovascular and pulmonary adverse events in patients treated withBCR-ABLinhibitors: Data from the FDA Adverse Event Reporting System

(2015) Jorge Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

(2015) Javid J. Moslehi et al.   JOURNAL OF CLINICAL ONCOLOGY

Possible effects of inhibition of IKr and IKs on field-potential waveforms in the human iPS cell-derived cardiomyocytes sheet

(2015) Junko Matsuo et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

(2014) N. P. Shah et al.   BLOOD

Assessment of Testing Methods for Drug-Induced Repolarization Delay and Arrhythmias in an iPS Cell–Derived Cardiomyocyte Sheet: Multi-site Validation Study

(2014) Yuji Nakamura et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes

(2013) Kimberly R. Doherty et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries

(2012) C. Nagaraj et al.   EUROPEAN RESPIRATORY JOURNAL

Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT Syndrome

(2012) Z. Lu et al.   Science Translational Medicine

CML biology for the clinician in 2011: six impossible things to believe before breakfast on the way to cure

(2011) B. Leber   Current Oncology

Inhibition of c-Src Tyrosine Kinase Prevents Angiotensin II–Mediated Connexin-43 Remodeling and Sudden Cardiac Death

(2011) Ali A. Sovari et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Src family kinases are essential for primary aggregation by Gi-coupled receptors

(2010) C. A. NASH et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

(2009) Alfonso Quintás-Cardama et al.   CANCER

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Translation of the Philadelphia chromosome into therapy for CML

(2008) B. J. Druker   BLOOD

Sensitive and reliable proarrhythmiain vivoanimal models for predicting drug-induced torsades de pointes in patients with remodelled hearts

(2008) A Sugiyama   BRITISH JOURNAL OF PHARMACOLOGY

Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels

(2008) De-Yong Zhang et al.   CELLULAR SIGNALLING

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

(2008) M. Brave et al.   CLINICAL CANCER RESEARCH

Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells

(2008) Yvonne Will et al.   TOXICOLOGICAL SCIENCES